Featured,Spotlight Stock,Trends & Articles PharmaTher Files For a Provisional Patent for Using Ketamine to Treat Diabetes and Obesity By Dennis Mutua April 28, 2021 Psychedelics Pharmaceutical company specializing in research, development and distribution of psychedelics PharmaTher Ther. (CSE: PHRM) (OTCQB: PHRRF) has filed for a provisional patent with the United States Patent and Trademark ...
Featured,Spotlight Stock,Trends & Articles MindMed Goes Public Becoming Second U.S Public Psychedelics Company By Dennis Mutua April 27, 2021 Biotechnology company engaging in developing and deploying psychedelics infused drugs to treat mental conditions Mind Medicine (MindMed) Inc. is set to start trading on NASDAQ on April 27 making it the second United States psyched...
Psychedelic Stocks,Trends & Articles Champignon Announces Revocation of Cease Trade Orders by Markets Regulators By Dennis Mutua April 26, 2021 Medical solutions company focused on mental illnesses and disorders with emphasis on psychedelics medicine Champignon Brands Inc. (CNSX: SHRM) (OTCQB: SHRMF) announced a cease trade order having been revoked by the Ontario Securit...
Featured,Spotlight Stock,Trends & Articles Revive Therapeutics Completes Research on Oral Thin Film Psilocybin By Dennis Mutua April 23, 2021 Life sciences company specializing on research and development of therapies for infectious diseases and rare disorders Revive Therapeutics Ltd (CNSX: RVV) announced successful completion of its research on oral thin film (OTF) del...
Featured,Spotlight Stock,Trends & Articles Proprietary Mushrooms Shows Efficacy in Killing Breast Cancer Cells Says Aion Therapeutics By Dennis Mutua April 22, 2021 Life Sciences Company concentrating on research and production of medical cannabis and psychedelics therapies Aion Therapeutics Inc. (CNSX: AION) announced its proprietary and patented combinatorial mushroom preparations AION F7 a...
Featured,Spotlight Stock,Trends & Articles PharmaTher Submits Phase 2 Clinical Trials Application for Using Ketamine to Treat Parkison’s Disease By Dennis Mutua April 21, 2021 Life Sciences company focusing on research and development of psychedelic pharmaceuticals PharmaTher Holding Ltd. (CSE: PHRM) (OTCQB: PHRRF) announced having submitted an application to commence its phase 2 clinical trials to asse...
Featured,Trends & Articles U.S Psychedelics Drug Market Expected to Reach $6.9 Billion by 2027 By Dennis Mutua April 20, 2021 A business intelligent report released on 19 April by Department for BioMedical Research (DBMR) suggests that the psychedelics drug market in the United States will be worth over $6.85 billion by the year 2027. This projection ...
Featured,Trends & Articles Therapeutic Goods Administration Reconsidering Making Psilocybin Easily Accessible to Psychiatrist for Treatment of Mental Health By Dennis Mutua April 19, 2021 Australian medicine and therapeutic regulatory authority Therapeutic Goods Administration (TGA) acknowledged having received an application to make accessibility of MDAM and magic mushrooms easier for psychiatrists so as to help i...